Can I Take Folate with Losartan?

The Short Answer: Folate Is Safe with Losartan for Most People

No published trial or case report documents a clinically meaningful interaction between folate and losartan. The two compounds travel entirely different metabolic paths. Folate is absorbed via the proton-coupled folate transporter (PCFT) and the reduced folate carrier (RFC) in the jejunum, whereas losartan is primarily metabolized by hepatic CYP2C9 to its active carboxylic acid metabolite E-3174 [1]. There is no overlap at the transporter or enzyme level that would raise absorption, distribution, metabolism, or excretion concerns.

Why Mechanism Matters Here

Losartan's pharmacokinetics are well characterized. About 14% of an oral dose is converted to E-3174, which is 10 to 40 times more potent at the AT1 receptor than the parent drug [2]. Neither folic acid nor 5-methyltetrahydrofolate (5-MTHF) inhibits CYP2C9 at physiological concentrations, so losartan's conversion to E-3174 is unaffected by folate supplementation.

Folate absorption, in contrast, is not impaired by losartan. Angiotensin II receptor blockade does not alter gastrointestinal pH enough to shift PCFT activity, which operates optimally at pH 5.5 [3]. Plasma folate levels measured in ARB-treated patients are statistically indistinguishable from those in matched controls not taking antihypertensives.

What the Interaction Databases Say

The Natural Medicines Database rates the folate, losartan combination as having "no known interaction" at standard supplemental doses. The Mayo Clinic drug interaction checker returns no contraindication. The FDA label for losartan (Cozaar) lists no dietary supplement interactions [4]. These are absence-of-signal findings, not absence of data.

How Losartan Works and Why Folate Status Is Clinically Relevant

Losartan competitively blocks the AT1 receptor, reducing vasoconstriction, aldosterone secretion, and sympathetic nervous system activation. It carries three FDA-approved indications: hypertension, stroke risk reduction in hypertensive patients with left ventricular hypertrophy, and diabetic nephropathy in patients with type 2 diabetes and proteinuria [4].

Cardiovascular Disease and Folate

Patients prescribed losartan typically carry elevated cardiovascular risk. Folate status is independently relevant in that population. Elevated plasma homocysteine, which rises when folate is deficient, is associated with a roughly 25% increase in coronary artery disease risk per 5 µmol/L increase in homocysteine [5]. Supplemental folate 0.5 to 5 mg/day reduces homocysteine by approximately 25% [6], though whether that reduction translates into reduced cardiovascular events remains debated.

The HOPE-2 trial (N=5,522) randomized patients with vascular disease to folic acid 2.5 mg plus B6 and B12 versus placebo. Homocysteine fell by 2.4 µmol/L in the active arm. There was no significant reduction in the primary composite of cardiovascular death, MI, or stroke (RR 0.95, 95% CI 0.84 to 1.07) [7]. This is worth knowing: folate supplementation is not a substitute for losartan's proven renoprotection or blood pressure control.

The RENAAL and LIFE Trials: Why These Patients Matter

Losartan's diabetic nephropathy indication comes from RENAAL (N=1,513), which showed a 16% reduction in the composite of doubling of serum creatinine, end-stage renal disease, or death (P<0.02) [8]. The LIFE trial (N=9,193) demonstrated a 13% reduction in the composite cardiovascular endpoint versus atenolol in hypertensive patients with LVH (P<0.021) [9]. Patients enrolled in these trials were never asked to avoid folate, and no subgroup signal suggesting folate interference was reported.

MTHFR Variants: When Folate Choice Changes

MTHFR gene variants affect how folate is processed. This is the area where clinical nuance matters most for losartan patients.

What MTHFR C677T Does

The MTHFR C677T polymorphism reduces enzyme activity by approximately 70% in homozygous (TT) individuals and 35% in heterozygous (CT) individuals [10]. Impaired MTHFR activity reduces conversion of 5,10-methylenetetrahydrofolate to 5-MTHF, the folate form that donates a methyl group to homocysteine for its conversion to methionine. Homocysteine accumulates. Folic acid (the synthetic oxidized form) may not fully compensate in TT individuals because it still requires MTHFR for conversion.

5-MTHF as the Preferred Form in MTHFR Patients

For patients with confirmed or suspected MTHFR C677T homozygosity, L-methylfolate (5-MTHF) bypasses the enzymatic bottleneck entirely [11]. Products such as Metafolin (calcium L-methylfolate) or Deplin provide 5-MTHF directly. Standard dosing in this context ranges from 400 mcg to 5 mg of L-methylfolate daily, depending on the clinical indication.

Patients on losartan for hypertension who happen to have MTHFR TT status may show persistently elevated homocysteine despite standard folic acid supplementation. Switching to 5-MTHF is a reasonable clinical step, not a drug interaction adjustment. Losartan itself does not change MTHFR enzyme activity [12].

Anticonvulsant Considerations: The Real Folate Depletion Risk

Patients occasionally receive losartan alongside anticonvulsants for comorbid conditions. Drugs such as phenytoin, carbamazepine, and valproate deplete folate through multiple mechanisms including increased hepatic metabolism of folate and reduced intestinal absorption [13]. In that combination, ensuring adequate folate intake becomes more clinically pressing. Losartan does not add to this depletion; only the anticonvulsant is the driver.

Folate and Blood Pressure: Does Supplementation Affect Antihypertensive Effect?

A specific concern some patients raise: could folate supplementation alter blood pressure and either amplify or blunt losartan's effect? The evidence does not support clinically meaningful blood pressure changes from folate alone in most adults.

Trial Evidence on Folate and Blood Pressure

A meta-analysis of 12 randomized controlled trials (N=803) examining folic acid supplementation and blood pressure found a mean reduction of 2.03 mmHg in systolic blood pressure (95% CI , 3.50 to , 0.56 mmHg, P<0.01) with doses of 5 to 10 mg/day [14]. That magnitude is modest and would not interfere with titration of losartan (typically dosed 25 to 100 mg/day).

One mechanistic pathway is through nitric oxide bioavailability. Folate reduces uncoupled endothelial nitric oxide synthase (eNOS) activity and may slightly increase NO production, producing mild vasodilation [15]. This is additive, not antagonistic, to losartan's vasodilatory effect. No trial has documented clinically significant hypotension from this combination.

Clinical Implication for Dose Titration

If a patient newly starting supplemental folate at 5 mg/day (a therapeutic dose used for high-risk pregnancies or hemolytic anemia) reports lightheadedness, blood pressure should be checked. The combination of losartan's AT1 blockade and folate's modest NO-mediated vasodilation could lower blood pressure by a few additional mmHg in sensitive individuals. Routine blood pressure monitoring every 4 to 8 weeks when any supplement is added to an antihypertensive regimen is standard practice.

Renal Function: The Monitoring Priority for Losartan Patients

Losartan is prescribed partly because it slows renal disease progression. Renal function therefore needs ongoing attention in this population, and folate has a narrow set of renal considerations.

Folate and Oxalate Excretion

High-dose folic acid (above 1 mg/day) may increase urinary oxalate excretion modestly in some individuals due to metabolic conversion of glyoxylate [16]. For patients with losartan-treated diabetic nephropathy and already-reduced eGFR, this is a theoretical concern rather than a documented clinical hazard at standard supplemental doses (400 to 800 mcg/day). Patients with eGFR <30 mL/min/1.73 m² or a history of calcium oxalate nephrolithiasis should discuss high-dose folic acid with their prescribing physician before starting.

Folic Acid in Renal Protection: The CSPPT Trial

The China Stroke Primary Prevention Trial (CSPPT, N=20,702) randomized hypertensive adults to enalapril 10 mg alone versus enalapril 10 mg plus folic acid 0.8 mg. First stroke was reduced by 21% in the combination arm (HR 0.79, 95% CI 0.68 to 0.93, P<0.003) [17]. A subgroup analysis published in JAMA Internal Medicine showed the enalapril plus folic acid combination reduced new-onset CKD by 56% compared to enalapril alone [18]. While CSPPT used an ACE inhibitor rather than an ARB, the renal protection finding supports the biological plausibility of combining an antihypertensive with folate rather than contraindicting it.

Practical Dosing and Timing

No dose-separation window is needed between folate and losartan. The two can be taken simultaneously.

Standard Supplemental Doses

• Dietary reference intake for adults: 400 mcg dietary folate equivalents (DFE) per day [19]
• Pregnancy and pre-conception: 400 to 800 mcg folic acid daily; 4 to 5 mg for women with prior neural tube defect pregnancy [20]
• Therapeutic homocysteine lowering: 0.5 to 5 mg folic acid daily
• MTHFR TT homozygotes: 400 mcg to 5 mg L-methylfolate (5-MTHF) daily, depending on clinical indication

For patients on losartan without specific folate deficiency or MTHFR concerns, a standard multivitamin containing 400 to 800 mcg folic acid covers the baseline requirement with no additional monitoring burden.

When to Use 5-MTHF Instead of Folic Acid

Switch to L-methylfolate if: MTHFR C677T TT genotype is confirmed, homocysteine remains above 15 µmol/L despite 3 months of standard folic acid, or the patient is taking medications that impair dihydrofolate reductase (e.g., methotrexate, trimethoprim) [21]. Losartan does not inhibit dihydrofolate reductase, so it does not by itself create an indication for 5-MTHF.

Monitoring Checklist for Patients Taking Both

Routine monitoring for patients on losartan who add folate supplementation should include the following:

Labs to Track

• Blood pressure at each visit or home monitoring log. Target <130/80 mmHg per the 2023 European Society of Hypertension guidelines [22].
• Serum creatinine and eGFR every 3 to 6 months in diabetic nephropathy patients per KDIGO 2022 guidelines [23].
• Serum potassium (ARBs raise potassium; folate does not affect this risk, but baseline should be established).
• Plasma homocysteine if MTHFR variant is known or cardiovascular risk is high. Target below 10 µmol/L [6].
• Serum folate or RBC folate if clinical deficiency is suspected (macrocytic anemia, unexplained fatigue, or glossitis).

Signs That Warrant a Physician Call

Symptoms such as persistent lightheadedness, new swelling, or worsening dyspnea after adding any supplement to an antihypertensive regimen should be evaluated. These are not expected from folate, but any significant blood pressure change (systolic drop of 10+ mmHg from baseline) during a supplement introduction period should prompt a medication review.

Special Populations

Pregnancy

Women taking losartan must stop it before conception or as soon as pregnancy is confirmed. Losartan is FDA Pregnancy Category D and carries a black-box warning for fetal toxicity, including oligohydramnios, renal dysplasia, and neonatal death [4]. In contrast, folate is strongly recommended in pregnancy, particularly 400 to 800 mcg folic acid starting at least one month before conception [20]. For a woman with hypertension who is planning pregnancy, the clinical action is to transition off losartan (to nifedipine or methyldopa) and ensure folate supplementation is in place, not to worry about any interaction between the two.

Older Adults

Adults over 65 have a higher prevalence of MTHFR heterozygosity, renal insufficiency, and polypharmacy. B12 deficiency also becomes more common with age and can mask itself as folate deficiency on standard CBC [24]. Checking both serum B12 and folate before starting supplementation in older adults on losartan is a reasonable precaution that costs little and prevents masking a B12 deficiency with high-dose folic acid.

Patients with Diabetes

Losartan's diabetic nephropathy indication means many patients carry type 2 diabetes. Metformin, commonly co-prescribed, mildly reduces B12 absorption with long-term use but does not meaningfully impair folate status [25]. Folate supplementation at standard doses is appropriate and safe in this group.

What Clinicians at HealthRX Typically Recommend

For a patient on losartan 50 mg daily for hypertension with no MTHFR testing, no renal impairment, and no anticonvulsant use, adding a multivitamin with 400 to 800 mcg folic acid carries no interaction risk and may provide modest cardiovascular benefit through homocysteine reduction. If homocysteine testing reveals levels above 15 µmol/L despite standard folic acid for 3 months, switching to L-methylfolate 1 mg daily and rechecking at 12 weeks is the practical next step.

Patients with diabetic nephropathy (eGFR <60 mL/min/1.73 m²) should limit folic acid to 800 mcg or less per day and discuss higher doses with their nephrologist before starting. The renal protection signal from CSPPT [17] is encouraging, but direct ARB plus folate RCT data in advanced CKD is still limited.